BDBM417031 (+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin-4-yl)propyl)-2-fluorophenyl)-1-(3-(aminomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 266j::US10633345, Compound 266j::US10689346, Compound 266j::US11203574, Compound 266j::US11230530, Compound 266j::US11685721, Compound 266j::US11708332, Compound 266j

SMILES Cc1cc(ccn1)C(N)(CCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1

InChI Key InChIKey=PYONXWOUVYIBRU-UHFFFAOYSA-N

Data  8 KI  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 417031   

TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataKi:  25.1nMAssay Description:Plasma kallikrein activity assay. The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50:  1.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50:  1.20nMAssay Description:Inhibition of purified human plasma kallikrein using H-D-Pro-Phe-Arg-pNA.2HCl as substrate measured after 3 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM417031((+)-N-(5-(1-amino-3-cyclopropyl-1-(2-methylpyridin...)
Affinity DataIC50:  3nMAssay Description:Inhibition of endogenous human plasma kallikrein using Z-Phe-Arg-AMC.HCl as substrate measured after 5 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed